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S. NUTINI, T. MARTINI AND R. RIGHI 
U.O. Pneumologia II, Azienda Ospedalieva Caveggi, Fivenze, Italy 
The aim of the present multicentre, open, randomized, parallel group study was to evaluate the efficacy and safety 
of salmeterol versus theophylline in asthmatic patients. A total of 112 patients were randomized: 56 received inhaled 
salmeterol (5Opg twice daily) and 50 oral dose titrated theophylline twice daily. The study lasted 12 months. The 
efficacy of both drugs was evaluated for the first 3 months of the study and the safety for a further 9 months. 
Spirometric measurements were carried out for the total duration of the study. Salmeterol showed a greater and 
more significant efficacy than theophylline in reducing both day- and night-time symptoms (P<O.OOl) and in 
reducing additional salbutamol requirement (P<O.OOl). The subjective assessment of efficacy by physicians and 
patients was in favour of salmeterol from the first month of treatment (P<O.OOl). Both drugs improved the quality 
of life as measured by the specific questionnaire ‘Living with Asthma’ with no significant differences. The total 
number of adverse events was slightly higher in the theophylline group compared with salmeterol (18 vs 9; P n.s.). 
Both salmeterol and theophylline increased morning and evening PEFR with no significant difference. FEV, and 
FVC increased in both groups of patients; the difference between the effects of the two treatments was not 
statistically significant at 12 months. Our study suggests that salmeterol has higher efficacy and safety than 
theophylline in long-term treatment of asthmatic patients. 
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Introduction 
According to the International Asthma Report (l), the use 
of long-acting bronchodilator is recommended for basic 
symptomatological treatment. Among the bronchodilating 
drugs, slow-release theophylline is commonly used for the 
control of nighttime symptoms because of its prolonged 
action (24); however, close monitoring of blood concen- 
trations is indispensable for maintaining a correct dosage 
while avoiding toxic side-effects which may even be 
potentially dangerous (5,6). 
Slow-release oral &agonists are effective in controlling 
symptoms, but they expose the patient to the risk of 
systemic side-effects such as cardiovascular stimulation, 
tremors and hypokalaemia (7,8). Several studies have 
shown that salmeterol is an effective drug in asthma treat- 
ment, especially for nocturnal and exercise-induced asthma 
(9-15) and that its use is not associated with relevant 
side-effects (16619). 
The efficacy and safety of salmeterol versus theophylline, 
both administered over a short period (from 7 to 28 days) 
to asthmatic p.atients have been recently evaluated (20-23). 
In these studies salmeterol was found to be more efficacious 
and safer than theophylline. 
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The aim of our trial was to evaluate the long-term effects 
of salmeterol versus slow-release theophylline administered 
over a 12-month period in asthmatic patients. 
Patients and Methods 
PATIENTS 
Patients aged over 18 years affected with bronchial asthma 
who fulfilled the following criteria at the end of the run-in 
period were enrolled. 
1. Forced expiratory volume in 1 s (FEV,) between 50 and 
80% of predicted value. 
2. There was an increase of FEV,, after 200,~g of salbuta- 
mol administered by a metered-dose inhaler, equal to or 
greater than 15% from basal values. 
3. Total symptom score was equal to or greater than 2, 
with a daily score of 1 or more, on at least 4 days during 
the last 7 days of the run-in period. The symptom score 
was graded from 0 (no symptoms at all) to 5 (symptoms 
with complete impairment of normal daily activity) for 
daily symptoms and from 0 to 4 (symptoms which 
prevented sleep throughout the night) for nocturnal 
symptoms. 
The exclusion criteria were severe sieroid-dependent 
asthma, lower respiratory tract infections or admittance to 
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hospital for asthma in the previous 28 days, serious sys- 
temic disease, renal insufficiency or liver insufficiency, con- 
gestive heart failure, active or symptomatic peptic ulcer, 
variable smoking habit, pregnancy or breast-feeding, hyper- 
sensitivity to &receptor agonists and/or to theophylline, 
and treatment with P-blockers, cimetidine, erythromycin, 
allopurinol, propranolol, labetalol, phenytoin, rifampicin, 
sulphinpyrazone, lithium, influenza vaccine, cyprofloxacin 
and interferon. Patients who were not able to use the 
metered-dose aerosol, or who were taking research drugs in 
the last month were also excluded. 
The trial was conducted according to the Helsinki decla- 
ration; each patient gave his or her informed consent at the 
moment of the enrolment. 
STUDY DESIGN 
The result was randomized, multicentre, open and with 
parallel groups. The choice of this type of design was a 
result of organizing difficulties for the management of a 
long-term treatment based on two different modalities of 
administration (oral versus aerosol) in a multicentre study. 
The trial design was as follows. 
Two-week Run-in 
Patients were not allowed to use the following drugs: 
/3,-agonists except rescue salbutamol; anticholinergics, 
methylxanthine. The patient was asked to record the peak 
flow values daily at morning and at evening and to note in 
his or her daily diary the symptoms. The use of rescue 
salbutamol as needed was also reported. These parameters 
were recorded by the patients up to the end of the first 
treatment period (3 months). 
Theophylline Titration of Varying Duration 
At the end of the run-in 150 mg of theophylline was 
administered twice daily to eligible patients; the dose was 
then increased by 150 mg twice daily every 47 days until a 
plasma theophyllinaemia level of lo-20 pug ml - I was 
reached. The theophyllinaemia level was determined with 
Acculevel Theophylline Assay Kits (24). 
First 3 Month Treatment Period [Evaluation of Efficacy) 
At the end of the titration period, the patients were 
randomly assigned to one of the following treatments: 
(1) 5Oyg inhaled salmeterol b.d. or (2) individually 
dose-titrated slow-release oral theophylline twice daily. 
Second 9 Month Treatment Period (Evaluation of Safety) 
The patients continued to take the drug for which they had 
been randomized. During this period, the patients were 
asked to record compliance with the treatment, additional 
salbutamol or other drugs and adverse events on the 
weekly record card. Respiratory functional data FEV, and 
forced vital capacity (FVC) were assessed during each 
medical visit. 
Two-week Follow-up 




The number and frequency of medical visits were as fol- 
lows: run-in period, three visits (one at the beginning, one 
after 1 week and two after 2 weeks); titration period, up to 
four visits, each at an interval of 3-7 days; first treatment 
period, three visits, each at 4 week intervals; second 
treatment period, three visits, each at 3 month intervals; 
follow-up, one visit at the end of follow-up. 
Data from the Patient’s Record Cavd 
The following were noted: peak flow assessed by mini- 
Wright’s peak flow meter (normal range) every day at 
morning and at evening; daily and nocturnal symptom 
score; use of additional salbutamol. 
Data Collected by the Researcher at each Visit 
FEV,, FVC, arterial blood pressure, heart rate, chest 
auscultation and evaluation of the efficacy of the treatment 
were noted. The highest FEV, value of three recordings was 
chosen. Bronchodilators were suspended for at least 4 h 
before the test. 
Data Collected from Questionnaire on Quality of Life 
(Living with Asthma, Italian Version) 
The questionnaire consisted of 12 questions. A score from 0 
to 2 was assigned to each response. The questionnaire was 
administered at the end of run-in, and after 3, 6, 9 and 12 
months of treatment. 
Laboratory Tests 
Electrocardiographic recording and haematochemical tests 
(haemochrome; sodium; potassium; calcium; bilirubinae- 
mia; total proteins; SGOT; SGPT; glycaemia; urea; creati- 
nine; uric acid; alkaline phosphate; urine test) were 
performed at the beginning and at the end of the trial. 
ADVERSE EVENTS 
All the adverse events were recorded, regardless of their 
apparent correlation with the test ‘drug. The following 
events were considered serious: death; events which placed 
the patients in danger of life; events which were disabling or 
unabling for patients; events which required or prolonged 
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hospitalization; any congenital anomaly; cancer; overdose. 
Other events were considered minor. 
STATISTICAL EVALUATION 
The statistical evaluation was carried out according to the 
‘intent to treat’ logic on all the 112 randomized patients. 
Analysis of Efficacy 
Peak expiratory flow variations were analysed as variations 
of the means in the two groups of patients assessed at the 
end of the run-in, after 1 month and after 3 months of 
treatment, and as the mean of the 3 months of treatment; 
the difference between the effects of the two treatments was 
evaluated using the analysis of covariance. 
The symptom score over time was evaluated by calculat- 
ing the proportion of days (nights) free of symptoms at the 
end of the first, second and third months of treatment, 
as well as the mean of all 3 months of treatment. The 
comparative analysis between the groups was determined 
using the x2 test. 
The analysis of the mean amount of additional salbuta- 
mol was evaluated with a similar method to that for the 
symptom score. 
The values of FEV, and FVC over time, the effect of 
treatments and the comparison between these were evalu- 
ated using the same method employed for the analysis of 
PEFR variations. The evaluations were made after 1, 3; 6, 9 
and 12 months of treatment. 
A x2 test was used to evaluate the overall efficacy of the 
two drugs and the variations in the auscultation results in 
both groups of patients. 
Analysis of Safety 
Arterial blood pressure and heart rate data were analysed in 
each group at the beginning and at the end of run-in and 
at all the other visits during the treatment period. The 
arithmetic mean, standard deviation and range were the 
descriptive synthetic indicators of the evolution of these 
variables. 
The result of the electrocardiographic record was 
evaluated separately for each patient. 
The haematological parameters were analysed by calcu- 
lating the number and percentage of patients in whom an 
increase or decrease in values was observed at the end of the 
study compared with the pre-treatment values. 
The significance of the changes was statistically evaluated 
with Student’s t test for paired data or with the sign test. 
Analysis of the Effects on the Quality of Life 
The quality of life was measured by evaluating the overall 
synthetic score for each patient (obtained by finding the 
arithmetic mean of the weight of the items to which the 
patient responded and multiplying by 10 to remove deci- 
mals). The overall score could range from a minimum of 0, 
an index of good quality of life, to a maximum of 20, an 
index of bad quality of life. 
The effect of each treatment on the overall synthetic score 
was evaluated by calculating the mean values of the index at 
the end of run-in and after 3, 6, and 9 months of treatment. 
The comparison between treatments was made by com- 
paring the mean values of the index after 3, 6, 9 and 12 
months of treatment using Student’s t test for independent 
data. 
Results 
Thirteen centres took part in the trial. Of the 112 patients 
randomized, 56 were treated with salmeterol and 56 with 
theophylline. 
Thirty-one of the randomized patients withdrew from 
the trial after the beginning of treatment. The reasons for 
withdrawal were the following: failure to return (12 
patients); adverse events (12 patients); concomitant diseases 
(three patients); other reasons (four patients). Withdrawal 
from the study due to adverse events was 3 times more 
frequent in the theophylline-treated group than in the 
salmeterol-treated one (nine cases versus three). 
Anthropometric, clinical and functional respiratory data 
(Table 1) of the patients were similar in both groups. 
Seven of the patients of the salmeterol group and five of 
the theophylline group were receiving inhaled anti- 
inflammatory agents (steroids or chromons); two patients 
of the salmeterol group and two of the theophylline group 
were receiving oral methyl prednisolone ~20 mg day - ‘. 
These treatments remained unchanged throughout the trial. 
EVALUATION OF THE EFFICACY 
PEER 
Both salmeterol and theophylline increased morning and 
evening PEFR values after 1 and 3 months of treatment as 
compared with the values found at the end of the run-in 
(Table 2). The difference between the two treatments was 
not statistically significant. 
The mean increase in morning PEFR over the 3 months 
of treatment was 35.1 1 min -’ in the salmeterol-treated 
group and 28.8 1 min - ’ in the theophylline-treated group. 
The mean increase in evening PEFR in the 3 months of 
treatment was 41.2 1 min -’ in the salmeterol group and 
26.5 1 min -’ in the theophylline group. 
symptoms 
Salmeterol showed a greater and more significant efficacy 
than theophylline in reducing both daytime and nighttime 
symptoms (Fig. 1). The rate of symptom-free days in the 
salmeterol-treated group increased by 31.3% at the end of 
the run-in to 60.4 and 70% after 1 and 3 months of 
treatment, respectively. In the theophylline-treated group 
this rate passed from 28% at the end of run-in to 51.7 and 
63.7% after 1 and 3 months of treatment, respectively. The 
rate of symptom-free days evaluated as the mean over the 
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TABLE 1. Anthropometric, clinical and functional respiratory data of the two groups of treated 
patients 
Salmeterol Theophylline 
No. of patients 
Age (years)* 
Sex (M:F) 
No. of smokers 
No. of patients with allergological positivity 
Duration of disease (yr)* 
No. of re-exacerbations in last year* 
No. of hospitalizations in last year* 
FVC (l)* 
FEV, (1)” 
PEFR (1 min - ‘) 
56 56 
45.5 (14) 47.9 (16.7) n.s. 
31:25 37:18 
4 5 
33 28 n.s. 
12.8 (9.5) 10.3 (8.0) n.s. 
2.6 (2.2) 2.1 (1.5) ns. 
0.5 (0%) 0.7 (1.2) n.s. 
3.28 (1.1) 3.21 (0.9) n.s. 
2.21 (0.8) 2.10 (0.6) n.s. 
359.9 (138.6) 331.6 (119.2) n.s. 
*Mean (SD); n.s., no statistical significance. 
TABLE 2. Mean values in litres per minute of PEFR measured in the morning and evening of the two 
patient groups 
Salmeterol Theophylline 
[mean (SD)] [mean (SD)] P 
Morning PEFR 
End of run-in 
After 1 month 
After 3 months 
1-3 months 
Evening PEFR 
End of run-in 
After 1 month 
After 3 months 
1-3 months 
359.9 (1386) 331.6 (119.2) ns. 
385.7 (131) 358.8 (107.7) ns. 
408.9 (135.6) 371.7 (104.6) ns. 
387.6 (133.8) 368.2 (105.7) ns. 
364.7 (139.2) 340.7 (122.8) n.s. 
396 (130.4) 364.6 (106.2) n.s. 
420.1 (135.6) 380.4 (103.6) n.s. 
398.4 (132.9) 373.9 (104.4) n.s. 
3 months of treatment was 65.7% in the salmeterol group 
and 56.8% in the theophylline group. 
The difference between the effects of the two treatments 
was statistically significant after 1 month (P<O.OOl), after 3 
months (PcO.005) and as the mean value over the 3 months 
(P<O.Ol). 
In the salmeterol group the rate of symptom-free nights 
increased from 32.8% at the end of run-in to 60.8% after 1 
month of treatment and 72.1% after 3 months. In the 
theophylline group these rates passed from 43.4 to 56.3 and 
61.2% after 1 and 3 months of treatment, respectively. The 
rate of symptom-free nights evaluated as the mean over the 
3 months was 65.7% in the salmeterol group and 60.2% in 
the theophylline group. The difference between the effects 
of the two treatments was statistically significant after 1 
month (P<O.O5), 3 months (P<O.OOl) and as the mean 
value over the 3 months of treatment (P-=0-01). 
Use of Rescue Salbutamol 
The theophylline-treated patients had more frequent 
recourse to additional salbutamol during both the 
day and the night than the salmeterol-treated ones 
The rate of days during which no additional salbutamol 
was required increased from 34.2% at the end of run-in to 
(Fig. 2). 
64.1 and 75.5 after 1 and 3 months of salmeterol treatment, 
respectively, and from 41.8% to 54.8 and 57.5% respectively 
in the theophylline group. The difference between the effects 
of the two treatments was statistically significant in favour 
of salmeterol after both 1 month (P<O.Ol) and 3 months 
($0.01). The percentage of days without recourse to 
additional salbutamol, evaluated as the mean over the 3 
months, was 68.7% in the salmeterol-treated group and 
57.2% in the theophylline-treated one. This difference was 
statistically significant (p<O.OOl). 
In the salmeterol group the percentage of nights without 
the need for additional salbutamol passed from 37.9% at 
the end of the run-in to 66.4% after 1 month of treatment 
and 74.3% after 3 months. In the theophylline group these 
percentages passed from 53.3% at the end of run-in to 
63.5% after 1 month and to 58.1% after 3 months. The 
percentage of nights during which patients did not use 
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FIG. 1. Percentage of symptom-free days and nights in 
salmeterol and theophylline groups: n , run-in; & 








Salmeterol Theophylline Salmeterol Theophylline 
Percentage of symptom-free days and nights in 
which no additional salbutamol was required in salm- 
eterol and theophylline groups: H, run-in; m2 1 month; 
0, 3 months. 
was 70.1 and 63.0% respectively in the salmeterol and 
theophylline groups. 
The difference between the effects of the two treatments 
was significant in favour of salmeterol both at the end of the 
third month of treatment (P<O.OOl) and as regards the 
mean over the 3 months (P<O.OOl). 
WC and FEV, 
Both salmeterol and theophylline produced an increase in 
FVC and FEV, values (Table 3). The difference between the 
effects of the two treatments was in favour of salmeterol at 
3 and 9 months for FVC and at 6 and 9 months for FEV,, 
but no difference was observed at the end of the study. 
Investigator’s and Patient’s Assessment 
Salmeterol obtained more favourable assessments than 
theophylline from both investigator and patient and this 
difference was already statistically significant from the first 
month. After 1 month, salmeterol was considered very 
effective or effective by the investigator in 72.7% of patients, 
vs 34% for theophylline (P<O,OOl). At the third month, 
these percentages became 76.4% for salmeterol and 52.3% 
for theophylline (P<O.Ol), while at the 12th month, they 
went up to 78.1% for salmeterol and down to 48.7% for 
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theophylline (P<O,OO4). After 1 month, salmeterol was 
considered effective or very effective by the patient in 67.9% 
of cases, vs 38% for theophylline (P<O.OOl). At the third 
month, these percentages became 78 and 45.4%, respect- 
ively (P<O.O03), while at the 12th month they increased to 
81.4% for salmeterol and 50% for theophylline (P<O.O2). 
Chest Ausculfafion 
The percentage of patients free of bronchospasm increased 
from 13% at the screening to 57.1% after 12 months of 
treatment in the salmeterol group, and from 18.1 to 55.3% 
in the theophylline group. The difference between the two 
groups of patients was not statistically significant. 
Qualify of Life 
Both sahneterol and theophylline improved the quality of 
life. 
In the salmeterol group the synthetic index passed from 
10.2 at the end of run-in to 9.7 after 3 months of treatment, 
8.6 after 6 months and 8.0 after 12 months. In the theo- 
phylline group the synthetic index passed from IO.4 at the 
end of run-in to 8.6 after 3 months of treatment, 7.5 after 
6 months and 6.7 after 12 months. 
The comparison between the two treatments showed no 
statistically significant differences 
EVALUATION OF SAFETY 
The cardiovascular parameters (arterial blood pressure and 
heart rate) did not change during the treatment period 
with either of the tested drugs. Neither salmeterol nor 
theophylline modified the electrocardiographic records. 
At the end of the trial the following haematochemical 
parameters changed as compared with baseline values: 
lymphocytes increased in 85.3% (P<O.OOl) of salmeterol 
subjects and in 83.9% (P<O,OOl) of theophylline subjects; 
monocytes and calcium decreased in 64.6% (P=O.Ol) and in 
58.8% (P=O.O5) respectively of salmeterol patients; eosi- 
nophils and alkaline phosphate decreased in 71% (WO.001) 
and 64.5% (P=O.O5) respectively of theophylline patients. 
Of the 56 patients treated with salmeterol, six (10.7%) 
reported at least one minor adverse event; these events were 
judged by the researcher as being almost certainly related to 
the administration of the drug in three patients. The total 
number of minor events was eight, and of these four (50%) 
were considered severe by the investigator. In the 
salmeterol-treated group, a serious adverse event occurred 
(death); this was judged by the investigator as not being 
related to the drug. 
Of the 56 patients treated with theophylline, three (5.3%) 
reported at least one minor adverse event, five (8.9%) an 
adverse event which was not classified by the investigator 
and two (3’5%) a serious adverse effect (one ‘pain all over’) 
and one ‘road traffic accident’, both judged by the investi- 
gator as not being related to the administration of the 
drug). In five of the eight patients reporting at least one 
minor or unclassified adverse effect, such effects are judged 
688 S. NLJTINI ET AL. 
TABLE 3. Mean values in litres of FEV, and FVC measured at the different examinations and mean 
between the values at the various examinations and the value at the end of run-in in the two patient 
groups 
Salmeterol Theophylline 
[mean (SD)] [mean (SD)] 
Salmeterol Theophylline 
(mean A) (mean A) P 
FVC 
End of run-in 3.35 (1.2) 3.26 (1.0) 
1 month 3.49 (1.2) 3.46 (0.9) +0.13 +0.12 ns. 
3 months 3.63 (1.2) 3.48 (0.9) + 0.23 +0.06 0.03 
6 months 3.61 (1.2) 3.54 (0.9) +0.21 +0,11 n.s. 
9 months 3.70 (1.2) 3.53 (0.9) +0.24 +0.06 0.02 
12 months 3.70 (1.2) 3.64 (0.9) +0.27 +0.18 n.s. 
FEV, 
End of run-in 2.22 (0%) 2.14 (0.6) 
1 month 2.45 (0.9) 2.36 (0.7) +0.25 +0.20 n.s. 
3 months 2.60 (0.9) 2.50 (0.7) +0.34 +0.24 n.s. 
6 months 2.65 (1.0) 2.49 (0.7) +0.40 +0.22 0.05 
9 months .2,74 (0.99) 2.49 (0.7) +0.43 +0.19 0.02 
12 months 2.75 (0.9) 2.56 (0.7) +0.45 +0.28 n.s. 
TABLE 4. Minor or unclassified adverse events occurring 
during the trial 
Salmeterol Theophylline 
Tachycardia 1 1 
Anxiety 1 0 
Excitability 1 1 
Precordial pain 1 0 
Headache 0 3 
Tremors 0 1 
Re-exacerbation of asthma 2 1 
Pyrosis 1 2 
Epigastralgia 0 3 
Nausea 0 2 
Abdominal pain 1 0 
Diarrhoea 0 2 
as being almost certainly or probably related to admin- 
istration of the drug. The total number of minor or 
unclassified adverse events was 16, and of these five (3 1.2%) 
were considered severe by the researcher. The types of 
minor or unclassified adverse events are shown in Table 4. 
The total number of adverse events was nine in the 
salmeterol group and 18 in the theophylline group (P n.s.). 
Discussion 
The results of our trial show that inhaled salmeterol in 
asthmatic patients at the dosage of 50,~g b.d. for a period 
of 12 months is associated with a better control of asthma 
and lower frequency of adverse events than individually 
dose-titrated, sustained-release theophylline administered 
twice daily. 
Salmeterol showed a greater and more significant efficacy 
than theophylline in reducing both day- and night-time 
symptoms and in reducing additional salbutamol require- 
ment. The subjective assessment of efficacy by physicians 
and patients was in favour of salmeterol from the first 
month of treatment. These findings are in agreement with 
those of previous studies (20-24) which had tested salm- 
eterol versus theophylline for shorter periods of time (from 
7 to 28 days). In asthmatic patients treated for 28 days, 
the complete disappearance of nocturnal symptoms was 
reported in 46639% of those treated with salmeterol and in 
15-26% of those treated with theophylline (20). Also, the 
treatment of asthmatic patients for a shorter period of time 
(7-15 days) resulted in a greater reduction in symptoms and 
use of additional salbutamol in the salmeterol-treated 
group than in the theophylline-treated one (21,22). More 
recently in a large multicentre European study which lasted 
4 weeks (23) the median percentage of nights with no 
asthma symptoms rose from 14% to 71% in patients treated 
with salmeterol and from 14% to 46% in patients treated 
with theophylline. Moreover, in the salmeterol group, 
rescue salbutamol use was significantly reduced during the 
night in comparison with the theophylline group. 
Also our study, carried out for a longer period of time 
(3 months) than the other studies previously reported, 
confirms the higher efficacy of salmeterol than theophylline 
in reducing daily (21) and nocturnal (21-23) symptoms and 
rescue salbutamol use (21-23). 
The improvement of quality of life is a desirable target in 
the treatment of bronchial asthma. A recent study has 
reported that patients with nocturnal asthma treated with 
salmeterol had more nights without awakenings, fewer 
nocturnal arousals and improved quality of life in compari- 
son with patients treated with theophylline (25). In our 
patients the improvement of quality of life was observed in 
both groups without significant difference, even though 
salmeterol was associated with a better control of daily and 
nocturnal symptoms than theophylline. We have no expla- 
nations for this discrepancy; probably quality of life is 
influenced by many other complex factors in addition to 
symptoms. 
Concerning the adverse effects which may be induced by 
bronchodilating agents the data of our study showed that 
the patients treated with salmeterol had fewer adverse 
events than those treated with theophylline, even though 
the difference was not statistically significant. These results 
were in agreement with those of previous studies, which 
reported five times less frequent adverse effects in 
salmeterol-treated patients than in theophylline-treated 
ones (20) and association of headache, nausea and vomiting 
with theophylline treatment (21;23). 
While all the studies previously cited indicate a greater 
efficacy of salmeterol in reducing asthma symptoms, which 
is associated with less need for additional salbutamol 
administration, the analysis of the respiratory function 
findings in both our trial and previous ones indicates an 
improvement with both salmeterol and theophylline, with 
salmeterol at only a slight advantage. 
In asthmatic patients treated for 28 days with salmeterol 
a statistically significantly higher increase in FEV, was 
found than in patients treated with theophylline+ ketotifen 
for a similar period, while no significant differences were 
ascertained in either FVC or PEFR (20). 
Salmeterol showed a significantly greater efficacy than 
theophylline in inducing both morning and evening PEFR 
improvement over a 15-day administration period; FEV, 
improved without any significant differences in both 
groups (21). 
The administration of salmeterol for 7 days led to a 
reduction in the number of days with PEFR decrease 
during the night and this effect was significantly higher than 
with theophylline. The effect of the two treatments on FEV, 
and FVC was not evaluated (22). 
No significant difference between salmeterol versus 
theophylline was observed for PEFR in a recent study 
during 4 weeks of treatment (23). 
The different behaviour of the various respiratory func- 
tion parameters in these studies is difficult to interpret. One 
explanation might be the difference in trial design as regards 
duration and the influence of the accuracy of patient 
training as regards the performance and hence the result of 
PEFR measurement. 
In our study both treatments determined an improve- 
ment over time in morning and evening PEFR, FEV, and 
FVC without significant difference at the end of the study. 
In conclusion, our trial suggests that salmeterol has 
higher efficacy and safety than theophylline in long-term 
treatment of asthmatic patients. It may thus be considered 
a first-choice long-lasting bronchodilator for those asth- 
matic patients who have clinical indications for treatment 
with this class of drugs. 
Acknowledgement 
The study is supported by A. Menarini, Industrie 
Farmaceutiche Riunite. 


















National Health, Lung and Blood Institute, National 
Institutes of Health, Bethesda. International consensus 
report on diagnosis and treatment of asthma. Eur 
Respir J 1992; 5: 601-641. 
Weinberger M, Hendeles L. Slow-release theophylline: 
rationale and basis for product selection. N Elzgl J Med 
1983;308:760-764. 
Zwillich CW, Neagley SR, Cicutto L, White DP: 
Martin RJ. Nocturnal asthma therapy: inhaled bitol- 
terol versus sustained-release theophylline therapy. Am 
Rev Respiv Dis 1989; 139: 470474. 
Heins M, Kurtin L, Oellerich M, Maes R, Sybrecht 
GW. Nocturnal asthma: slow-release terbutaline versus 
sustained-release theophylline. Eur Respiy J 1988; 1: 
306-310. 
Woodcock AA, Johnson MA, Geddes DM. Theophyl- 
line prescribing, serum concentrations and toxicity. 
Lamet 1983; 2: 610-612. 
Miech RP, Stein M. Methylxanthines. Clin Chest Med 
1986; 6 (3): 331-340. 
Zeith S, Rolles C, Antolainen I et al. An open, multi- 
centre, crossover comparison of albuterol controlled- 
release tablets and individually titrated slow-release 
theophylline in the treatment of childhood asthma. Am 
Rev Respir Dis 1988; 137: 33 
Cochrane GM, Vyse T. The acceptability of two differ- 
ent oral bronchodilators, a comparison. Am Rev Respiy 
Dis 1988; 137: 235. 
Pearlmann DS, Chervinksy P, La Force C et al. A 
comparison of salmeterol with salbutamol in the treat- 
ment of mild to moderate asthma. N Engl J Med 1992; 
327: 1420-1425. 
Britton MG, Earnshaw JS, Palmer JBD. A 12-month 
comparison of salmeterol with salbutamol in asthmatic 
patients. Eur Respir J 1992; 5: 1062-1067. 
Fitzpatrick MF, McKay T, Driver H et nl. Salmeterol 
in nocturnal asthma; a double blind, placebo- 
controlled trial of a long-acting inhaled beta 2 agonist. 
Br Med J 1990; 301: 1365-1368. 
Palmer JBD, Stuart AM, Shepherd GL et al. Inhaled 
salmeterol in the treatment of patients with moderate- 
to-severe reversible obstructive airway disease: a 
3-month comparison of the efficacy and safety of 
twice-daily salmeterol (100 mcg) with salmeterol 
(500 mcg). Respir Med 1992; 86: 409417. 
Anderson SD, Rodwell LT; Toit JD et al. Duration of 
protection by inhaled salmeterol in exercise-induced 
asthma. Clzest 1991; 100: 1254-1260. 
Kemp J; Bukstein D, Busse W. Effective salmeterol, 
salbutamol and placebo in the prevention of exercise- 
induced bronchospasm. Chest 1993; 104 (Suppl.): 10s. 
D’Alonzo GE. Efficacy of inhaled salmeterol in the 
treatment of asthma. Eur Respir Rev 1995; 5 (27): 
128-132. 
Palmer J, Hyland ME. Salmeterol in clinical practice: 
comparative and safety studies, quality of life studies. 
Em Respiv Rev 1991; 1: 301-303. 
690 S. NUTINI ET AL 
17. Kemp J, Bierman W, Cochetto DM. Dose-response 
study of inhaled salmeterol in asthmatic patients with 
24-spirometry and Holter monitoring. Ann Allergy 
1993; 70: 316-322. 
18. Castle W, Fuller R, Hull J, Palmer J. The Serevent 
nationwide surveillance study. Bv Med J 1993; 306: 
10341037. 
19. Fuller R. Safety of salmeterol in the treatment of 
asthma. Eur Respiv Rev 1995; 5 (27): 133-137. 
20. Muir JF, Bertiin L, Georges D, French Multicentre 
Study Group. Salmeterol versus slow-release theophyl- 
line combined with ketotifen in nocturnal asthma: a 
multicentre trial. Eur Respir J 1992; 5: 1197-1200. 
21. Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy 
and safety of inhaled salmeterol and individually 
dose-titrated, sustained-release theophylline in patients 
with reversible airway disease. Respiv Med 1994; 88: 
599-607. 
22. Braun H, Koper I, Ukena D, Sybrecht GW. Salmeterol 
compared with theophylline in the treatment of noctur- 
nal asthma. Eur Respir J 1993; 6 (Suppl. 17): 3833. 
23. Paggiaro PL, Giannini D, Di Franc0 A, Testi R on 
behalf of a European Study Group. Comparisons of 
inhaled salmeterol and individually dose-titrated slow- 
release theophylline in patients with reversible airway 
obstruction. EUP Respir J 1996; 9: 1689-1695. 
24. Vaughan LM, Weinberger MM, Milavetz G et al. 
Multicentre evaluation of disposable visual measuring 
device to assay theophylline from capillary blood 
sample. Lancet 1986; 1: 184186. 
25. Selby C, Engleman HM, Fitzpatrick MF et al. Inhaled 
salmeterol or oral theophylline in nocturnal asthma? 
Am J Respiv Cvit Care Med 1997; 155: 104108. 
Appendix 
The following investigators collaborated in the study: C. 
Aversa (Respiratory Physiopathology, Galateo Hospital, 
Lecce); P. Alimonti (Respiratory Physiopathology, S. 
Pietro Hospital, Roma); P. Altucci (Department of System- 
atic Medicine, IInd Polyclinic, Napoli); Buscarini (1st Medi- 
cal Division, Civic Hospital, Piacenza); A. Cirocco 
(Bronchopneumology, Monforte, Avellino); M. Di 
Gioacchino (Allergology, SS Annunziata Hospital, Chieti); 
T. Di Perri (Medical Clinics, Le Scotte New Polyclinic, 
Siena); G. Ferrara (Pneumology, Cervello Hospital, 
Palermo); S. Marsico (Respiratory Physiopathology, 
Polyclinic, Catanzaro); R. Petreni (Pneumology, Civic 
Hospital, Arezzo); G. Picciolo (General Therapy and 
Cardiocirculatory Rehabilitation, Piemonte Hospital, 
Messina); G. Piu (Allergology, Brotzu Hospital, Cagliari). 
